Merck & Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance).
Hypercholesterolemia, a type of hyperlipidemia, is a disorder in which there are elevated LDL cholesterol levels in the blood. It affects approximately 86 million adults in the U.S. and is a major risk driver for ASCVD, accounting for 85% of cardiovascular deaths.
